Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma

Sheldon L. Spector, Lewis J. Smith, Mitchell Glass, Bruce K. Birmingham, Edwin A. Bronsky, Karen D. Dunn, James E. Fish, Jay Grossman, William Howland, Margaret C. Minkwitz, Julie S. Larsen, Robert A. Nathan, Stephen I. Rennard, Edward S. Schulman, Allen Segal, James M. Seltzer

Research output: Contribution to journalArticle

326 Citations (Scopus)

Abstract

The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo- controlled, dose-ranging study. Subjects who entered the trial had been chronically treated for asthma with β agonist alone or in combination with theophylline. Subjects were randomized to treatment with twice daily doses of ICI 204,219 (5, 10, or 20 mg) or placebo if they had an FEV1 between 40 and 75% of predicted values without bronchodilator therapy and a daytime asthma score > 10 (range 0 to 21 per wk) for 7 consecutive d. Efficacy was evaluated from the results of symptom assessments, pulmonary function tests, and rescue medication use. Of 276 subjects randomized to treatment, 266 (10 mg, n = 66; 20 mg, n = 67; 40 mg, n = 67; placebo, n = 66) were analyzed for efficacy. Diary card assessments showed that treatment with increasing doses of ICI 204,219 linearly improved five efficacy criteria without increasing the number or severity of adverse events. The 40 mg dose was more effective than placebo (p < 0.05) in reducing nighttime awakenings, first morning asthma symptoms, the daytime asthma score, and albuterol use and in increasing evening peak expiratory flow (PEF) rates as well as FEV1. Compared with baseline measurements, the 40 mg dose decreased awakenings by 46%, albuterol use by 30%, and daytime symptoms by 26% and increased FEV1 by 11%. ICI 204,219 improves objective and subjective measures of asthma severity in moderately ill asthmatic subjects and may provide a new treatment option for the disease.

Original languageEnglish (US)
Pages (from-to)618-623
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume150
Issue number3
DOIs
StatePublished - Sep 1994

Fingerprint

Leukotriene Antagonists
Asthma
Placebos
Albuterol
Therapeutics
Peak Expiratory Flow Rate
Symptom Assessment
Bronchodilator Agents
Respiratory Function Tests
Theophylline
leukotriene D4 receptor
zafirlukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. / Spector, Sheldon L.; Smith, Lewis J.; Glass, Mitchell; Birmingham, Bruce K.; Bronsky, Edwin A.; Dunn, Karen D.; Fish, James E.; Grossman, Jay; Howland, William; Minkwitz, Margaret C.; Larsen, Julie S.; Nathan, Robert A.; Rennard, Stephen I.; Schulman, Edward S.; Segal, Allen; Seltzer, James M.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 150, No. 3, 09.1994, p. 618-623.

Research output: Contribution to journalArticle

Spector, SL, Smith, LJ, Glass, M, Birmingham, BK, Bronsky, EA, Dunn, KD, Fish, JE, Grossman, J, Howland, W, Minkwitz, MC, Larsen, JS, Nathan, RA, Rennard, SI, Schulman, ES, Segal, A & Seltzer, JM 1994, 'Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma', American Journal of Respiratory and Critical Care Medicine, vol. 150, no. 3, pp. 618-623. https://doi.org/10.1164/ajrccm.150.3.8087328
Spector, Sheldon L. ; Smith, Lewis J. ; Glass, Mitchell ; Birmingham, Bruce K. ; Bronsky, Edwin A. ; Dunn, Karen D. ; Fish, James E. ; Grossman, Jay ; Howland, William ; Minkwitz, Margaret C. ; Larsen, Julie S. ; Nathan, Robert A. ; Rennard, Stephen I. ; Schulman, Edward S. ; Segal, Allen ; Seltzer, James M. / Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. In: American Journal of Respiratory and Critical Care Medicine. 1994 ; Vol. 150, No. 3. pp. 618-623.
@article{f4f0d1ae54a34addadbf24ca4d6484d8,
title = "Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma",
abstract = "The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo- controlled, dose-ranging study. Subjects who entered the trial had been chronically treated for asthma with β agonist alone or in combination with theophylline. Subjects were randomized to treatment with twice daily doses of ICI 204,219 (5, 10, or 20 mg) or placebo if they had an FEV1 between 40 and 75{\%} of predicted values without bronchodilator therapy and a daytime asthma score > 10 (range 0 to 21 per wk) for 7 consecutive d. Efficacy was evaluated from the results of symptom assessments, pulmonary function tests, and rescue medication use. Of 276 subjects randomized to treatment, 266 (10 mg, n = 66; 20 mg, n = 67; 40 mg, n = 67; placebo, n = 66) were analyzed for efficacy. Diary card assessments showed that treatment with increasing doses of ICI 204,219 linearly improved five efficacy criteria without increasing the number or severity of adverse events. The 40 mg dose was more effective than placebo (p < 0.05) in reducing nighttime awakenings, first morning asthma symptoms, the daytime asthma score, and albuterol use and in increasing evening peak expiratory flow (PEF) rates as well as FEV1. Compared with baseline measurements, the 40 mg dose decreased awakenings by 46{\%}, albuterol use by 30{\%}, and daytime symptoms by 26{\%} and increased FEV1 by 11{\%}. ICI 204,219 improves objective and subjective measures of asthma severity in moderately ill asthmatic subjects and may provide a new treatment option for the disease.",
author = "Spector, {Sheldon L.} and Smith, {Lewis J.} and Mitchell Glass and Birmingham, {Bruce K.} and Bronsky, {Edwin A.} and Dunn, {Karen D.} and Fish, {James E.} and Jay Grossman and William Howland and Minkwitz, {Margaret C.} and Larsen, {Julie S.} and Nathan, {Robert A.} and Rennard, {Stephen I.} and Schulman, {Edward S.} and Allen Segal and Seltzer, {James M.}",
year = "1994",
month = "9",
doi = "10.1164/ajrccm.150.3.8087328",
language = "English (US)",
volume = "150",
pages = "618--623",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma

AU - Spector, Sheldon L.

AU - Smith, Lewis J.

AU - Glass, Mitchell

AU - Birmingham, Bruce K.

AU - Bronsky, Edwin A.

AU - Dunn, Karen D.

AU - Fish, James E.

AU - Grossman, Jay

AU - Howland, William

AU - Minkwitz, Margaret C.

AU - Larsen, Julie S.

AU - Nathan, Robert A.

AU - Rennard, Stephen I.

AU - Schulman, Edward S.

AU - Segal, Allen

AU - Seltzer, James M.

PY - 1994/9

Y1 - 1994/9

N2 - The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo- controlled, dose-ranging study. Subjects who entered the trial had been chronically treated for asthma with β agonist alone or in combination with theophylline. Subjects were randomized to treatment with twice daily doses of ICI 204,219 (5, 10, or 20 mg) or placebo if they had an FEV1 between 40 and 75% of predicted values without bronchodilator therapy and a daytime asthma score > 10 (range 0 to 21 per wk) for 7 consecutive d. Efficacy was evaluated from the results of symptom assessments, pulmonary function tests, and rescue medication use. Of 276 subjects randomized to treatment, 266 (10 mg, n = 66; 20 mg, n = 67; 40 mg, n = 67; placebo, n = 66) were analyzed for efficacy. Diary card assessments showed that treatment with increasing doses of ICI 204,219 linearly improved five efficacy criteria without increasing the number or severity of adverse events. The 40 mg dose was more effective than placebo (p < 0.05) in reducing nighttime awakenings, first morning asthma symptoms, the daytime asthma score, and albuterol use and in increasing evening peak expiratory flow (PEF) rates as well as FEV1. Compared with baseline measurements, the 40 mg dose decreased awakenings by 46%, albuterol use by 30%, and daytime symptoms by 26% and increased FEV1 by 11%. ICI 204,219 improves objective and subjective measures of asthma severity in moderately ill asthmatic subjects and may provide a new treatment option for the disease.

AB - The efficacy of 6 wk of therapy with oral ICI 204,219, a selective leukotriene D4 (LTD4) receptor antagonist, was evaluated in subjects with moderate asthma during a multicenter, double-blind, randomized, placebo- controlled, dose-ranging study. Subjects who entered the trial had been chronically treated for asthma with β agonist alone or in combination with theophylline. Subjects were randomized to treatment with twice daily doses of ICI 204,219 (5, 10, or 20 mg) or placebo if they had an FEV1 between 40 and 75% of predicted values without bronchodilator therapy and a daytime asthma score > 10 (range 0 to 21 per wk) for 7 consecutive d. Efficacy was evaluated from the results of symptom assessments, pulmonary function tests, and rescue medication use. Of 276 subjects randomized to treatment, 266 (10 mg, n = 66; 20 mg, n = 67; 40 mg, n = 67; placebo, n = 66) were analyzed for efficacy. Diary card assessments showed that treatment with increasing doses of ICI 204,219 linearly improved five efficacy criteria without increasing the number or severity of adverse events. The 40 mg dose was more effective than placebo (p < 0.05) in reducing nighttime awakenings, first morning asthma symptoms, the daytime asthma score, and albuterol use and in increasing evening peak expiratory flow (PEF) rates as well as FEV1. Compared with baseline measurements, the 40 mg dose decreased awakenings by 46%, albuterol use by 30%, and daytime symptoms by 26% and increased FEV1 by 11%. ICI 204,219 improves objective and subjective measures of asthma severity in moderately ill asthmatic subjects and may provide a new treatment option for the disease.

UR - http://www.scopus.com/inward/record.url?scp=0028103864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028103864&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.150.3.8087328

DO - 10.1164/ajrccm.150.3.8087328

M3 - Article

C2 - 8087328

AN - SCOPUS:0028103864

VL - 150

SP - 618

EP - 623

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -